A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)
Latest Information Update: 08 Oct 2021
Price :
$35 *
At a glance
- Drugs Ebselen (Primary)
- Indications Noise-induced hearing loss
- Focus Therapeutic Use
- Acronyms PANIHL
- Sponsors Sound Pharmaceuticals
- 22 Aug 2018 Planned End Date changed from 1 Sep 2019 to 1 Oct 2021.
- 22 Aug 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Jun 2021.
- 22 Aug 2018 Planned initiation date changed from 1 Feb 2018 to 1 Nov 2018.